FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending May 2009
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

 

 
Notification of Transactions of Directors, Persons Discharging 
Managerial Responsibility or Connected Persons


The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company and 
the under-mentioned
 persons
 on 11 May 2009 of an increase in their notional interests
 in Ordinary shares at a price of £10.39 per share and Ordinary Share ADRs at a price of $30.85 per ADR
 
following the notional re-investment of the dividend to be paid to shareholders on 
9 July
 2009.



Ordinary 
shares
ADRs
Mr A 
P 
Witty
5,302.48

Mr J 
S 
Heslop
3,034.13

Dr M 
M 
Slaoui

1,965.07
Mrs C E Bruck Slaoui

79.47
Mr S M Bicknell
256.60

Mr J
 M
 Clarke
2,225.03

Mr M Dunoyer
838.00

Mr E J Gray
881.14

Mr S A Hussain
627.86

Mr D Learmouth
614.05

Mr W C Louv

711.98
Mr D 
J 
Phelan

1,096.45
Dr D Pulman

711.98
Mr D S Redfern
340.98

Mr J R Stéphenne 
768.6
5

Ms C Thomas
256.60

Mr D E Troy

776.88


 

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to 
transaction
s
 notified in accordance with
 Disclosure and Transparency Rules 3.1.4R(1)(a).
 

V A Whyte
Deputy 
Company Secretary

11
 
May 
2009

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: May, 11 2009

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc